Phacolytic glaucoma be incorporated in the rehabilitation process to reduce the risk of infection of the eye and to allow for an effective healing process. Additionally, the patient must consistently visit the specialist in order to ensure a successful removal of phacolytic glaucoma. There may be a need for medical therapies which treat arising issues for the eye such as inflammation. These medical therapy procedures for phacolysis consist of controlling the intraocular pressure which may include the use of topical steroids in order to decrease inflammation in the eye, and mydriatics in order to prevent the formation of synechiae. It is found
Minimally invasive glaucoma surgery vision and take extra time to recover. The surgery site can scar over time and the pressure can go back up. In early 2014, the NeoMedix received a warning letter from FDA regarding marketing practices. Minimally invasive glaucoma surgery Micro-invasive glaucoma surgery (MIGS) is the latest advance in surgical treatment for glaucoma, which aims to reduce intraocular pressure by either increasing outflow of aqueous humor or reducing its production. MIGS comprises a group of surgical procedures which share common features. MIGS procedures involve a minimally invasive approach, often with small cuts or micro-incisions through the cornea that causes the least